Atay Oguzhan sold $983K of BLLN

Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $118.00 ($0.98M total) on 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 30, 2026, 10:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The sale reduces insider ownership to zero, which may be interpreted as a lack of confidence, but the pre‑arranged plan tempers the signal.

02

Market read

Insider sell of nearly $1M by the CEO is noteworthy for a micro‑cap, but the pre‑arranged nature limits actionable insight.

03

What to watch

The 10b5‑1 plan indicates the sale was pre‑planned, reducing the informational content of the trade.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; investors watch them for signals of confidence.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Chairman and CEO Atay Oguzhan sold 8,333 shares for $983,294 via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $983K sale by the CEO is material for a micro‑cap and may prompt short sellers.

Market effects

Minimal; the sale is company‑specific and does not affect the broader sector.

None; the transaction is isolated to BillionToOne.

None

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • BillionToOne, Inc.

    Micro‑cap listed on Nasdaq under ticker BLLN.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.